Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus DIFLORASONE DIACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus DIFLORASONE DIACETATE.
ARAZLO vs DIFLORASONE DIACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Diflorasone diacetate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions. It induces phospholipase A2 inhibitory proteins (lipocortins), thereby controlling the biosynthesis of potent mediators of inflammation like prostaglandins and leukotrienes.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply a thin film to affected skin areas twice daily (every 12 hours). Use the lowest effective strength and duration.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life of approximately 5.7 hours (range 4.4–7.1 h) after topical application; prolonged in hepatic impairment.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily renal (≤5% unchanged); extensive hepatic metabolism with biliary/fecal elimination of metabolites; total recovery: ~60% in urine (metabolites), ~30% in feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid